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Edited by Veli-Pekka LehtoAbstract The angiotensin converting enzyme breakdown prod-
uct of bradykinin, bradykinin 1–5 (RPPGF), inhibits thrombin-
induced human or mouse platelet aggregation. RPPGF binds
to the exodomain of human protease-activated receptor 1
(PAR1). Studies determined if RPPGF also binds to the exodo-
main of human PAR4. RPPGF binds to a peptide of the throm-
bin cleavage site on PAR4. Recombinant wild-type and mutated
exodomain of human PAR4 was prepared. The N-terminal argi-
nine on RPPGF binds to the P2 position or proline46 on PAR4 to
block thrombin cleavage. These data indicate that RPPGF influ-
ences thrombin activity by binding to the thrombin cleavage site
on both PAR4 and PAR1.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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RPPGF1. Introduction
Protease-activated receptors (PAR) are novel G-protein
coupled receptors that are activated by the proteolysis of
an N-terminal exodomain [1]. Upon proteolysis, the newly
formed N-terminus acts as a tethered ligand to activate the
receptor and initiate multiple signaling cascades via heterotri-
meric G-proteins [2,3]. There are four PARs (PAR1–4) that
make up this family of proteins. PAR1, 3 and 4 are activated
by thrombin, whereas PAR2 is activated by trypsin or tryp-
tase [4]. Thrombin is a major platelet agonist by activating
protease activated receptors 1 and 4 (PAR1 and 4) [5].
Thrombin-induced platelet activation initiates signaling path-
ways that lead to platelet shape change, degranulation, and
aggregation. Thrombin activates PAR1 at concentrations
10-fold less than PAR4, but activation of PAR4 provides
a longer stimulus [6,7]. These receptors have distinct roles
and both receptors contribute to physiologic hemostasis. A
number of PAR1 activation antagonists have been developedAbbreviations: RPPGF or BK1–5, bradykinin 1–5; PAR1 & 4, prote-
ase-activated receptors 1 & 4; SIL12, peptide SILPAPRGYPGQ
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doi:10.1016/j.febslet.2004.11.041[8–10]. However, in order to effectively inhibit human throm-
bin-induced platelet activation, both PAR1 and PAR4 activa-
tion must be blocked.
The terminal angiotensin converting enzyme (ACE) break-
down product of bradykinin, bradykinin 1–5 (BK1–5) or
peptide Arg-Pro-Pro-Gly-Phe (RPPGF), inhibits thrombin-in-
duced platelet aggregation, binds to the active site of thrombin
and binds to amino acids L38DPR41 in the P4–P1 position on
the exodomain of PAR1 to prevent the proteolysis and activa-
tion of this receptor [11]. Further, RPPGF and an RPPGF
analog, rOicPGF, individually, inhibit the active site of both
thrombin and factor VIIa [12]. Additional studies show that
RPPGF at 2 mg/kg IP or rOicPGF at 0.44 mg/kg IP signifi-
cantly delays mouse carotid artery thrombosis in the Rose
Bengal Model [12]. Furthermore, both RPPGF and rOicPGF
inhibit c-thrombin induced mouse platelet aggregation in
platelet-rich plasma and prolong the bleeding time in the
mouse [12]. In contrast to human platelets, mouse platelets
do not express PAR1; rather, they express PAR3 and PAR4.
In mouse platelets, PAR4 is the signaling receptor, whereas
PAR3 is a cofactor for PAR4 activation [13]. Therefore, the
ability of RPPGF or rOicPGF to inhibit the activation of
mouse platelets suggests that these peptides interact with
mouse PAR4 in addition to human PAR1 [11,12]. In this re-
port, we demonstrate that the arginine of the ACE breakdown
product of bradykinin, RPPGF, or an analog, rOicPGF, also
binds to proline46 at the P2 position of the exodomain of hu-
man PAR4 to inhibit thrombin cleavage of human PAR4
exodomain. These data indicate a single naturally occurring
peptide that interferes with thrombins interaction with both
PAR1 and PAR4.2. Materials and methods
2.1. Materials
The abbreviation used for the synthetic amino acid (2S, 3aS, 7aS)-
octahydroindol-2-carboxilic acid is Oic. Standard single capital letter
abbreviations are used for L amino acids and lowercase letters are used
to designate D amino acids. Peptides RPPGF, scrambled RPPGF,
FPRPG and D-Arg-Oic-Pro-Gly-Phe (rOicPGF), Arg-Pro-Pro-Gly-
Phe-Lys-biotin (RPPGFK-biotin), biotin-Gly-Arg-Pro-Pro-Gly-Phe
(biotin-GRPPGF), RPPGC, SILPAPRGYPGQ (SIL12) and biotin-
SIL12 were synthesized by Multiple Peptide Systems, Inc. (San Diego,
CA). Peptide Trp-Pro-Pro-Gly-Phe (WPPGF) was synthesized by the
Protein and Carbohydrate Structure Core, University of Michigan
(Ann Arbor, MI). All peptides used in these studies were greater
than >95% pure by reverse-phase HPLC. The purified peptides wereblished by Elsevier B.V. All rights reserved.
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trometry for homogeneity. The peptides were colorless, odorless, and
soluble in water.
2.2. Cloning and mutagenesis of PAR4 exodomain
The cDNA of human PAR4 from (Gly18-Arg78) was prepared from
HEL cell mRNA by RT-PCR and cloned into pET19b or pET31b
(Novagen, Madison, WI). The cDNA of human PAR1 exodomain
(Ala26-Ser99) has been described [11]. The pET31b constructs were
used for bacterial expression of recombinant PAR1 exodomain
(PAR1-wt), PAR4 exodomain (PAR4-wt) and PAR4 exodomain mu-
tants because this system produced higher yields of recombinant pro-
tein and eliminated the His tag (see below).
Mutations of the PAR4 exodomain were generated by alanine substi-
tution using the PAR4-wt-pET19b as the starting material with the
exception of PAR4-P44A/P46A, in which PAR4-P46A was used as the
starting material. Mutations were created by using overlapping mutag-
enizing oligonucleotides and PCR. Two sets of oligonucleotides were
used to create each mutant: outside oligonucleotides hybridizing 5 0
and 3 0 of the coding sequence and internal, overlapping oligonucleotides
of opposite orientation containing themutatednucleotides to change the
codons to the desired amino acid residue. The outside primers were T7-
promoter (T7p) (5 0 end, sense) and T7 terminator (T7t) (3 0 end, anti-
sense). Themutagenizing internal oligonucleotides are shown in Table 1.
2.3. Recombinant protein production
Purified recombinant exodomain of PAR1, PAR4, or PAR4 mu-
tants was prepared from 2 liter cultures of Escherichia coli
BLR(DE3) with the plasmid pET31b containing the PAR4 cDNA
that were grown to mid-log phase at 37 C in Luria broth, followed
by induction with 1 mM IPTG for 5 h. After induction, the bacteria
were harvested by centrifugation (10 min, 5000 · g) and the pellet
was resuspended in binding buffer (40 mM Tris–HCl and 500 mM
NaCl, pH 7.4) containing 0.3 mg/ml lysozyme. The extracts were
then incubated on ice for 15 min for partial lysis and then stored
at 80 C overnight. After thawing to complete the lysis, 1 ml of
both RNase A (1 mg/ml) and DNase A (1 mg/ml) was added to
the suspension followed by incubation at 37 C for 1 h. Bacterial ly-
sates were centrifuged at 5000 · g for 15 min and the pellet was
resuspended in binding buffer containing 5 mM imidazole and puri-
fied with nickel-chelate chromatography followed by treatment with
CNBr to remove the KSI fusion protein and the His tag according
to the manufacturers protocol (Novagen, Madison, WI). The final
recombinant proteins were further purified by HPLC. The integrity
of the expressed PAR4 exodomain was verified by MALDI-TOF
mass spectrometry and N-terminal sequencing.Table 1
Oligonucleotides to prepare PAR4 mutants






S-PAR4-P46A 5 0-CCTGCCGCACGCGGCTAC-3 0
A-PAR4-P46A 3 0-TAGGACGGACGGCGTGCGCC-50
S-PAR4-P44A/P46A 5 0-CAATCCTGGCTGCCGCA-3 0
A-PAR4-P44A/P46A 3 0-GTTAGGACCGACGGCGT-5 0
Overlapping PCR techniques were used to generate PAR4 alanine
substitution mutants at Pro44, Pro46 or Pro44 and Pro46 as described in
Section 2. Oligonucleotides are labeled ‘‘S’’ for the sense strand and
‘‘A’’ for the antisense strand; the mutated codons are underlined in
bold.
aRepresents the amino acid sequence of the thrombin cleavage site on
human PAR4 using the single letter abbreviation code for each amino
acid.
bRepresents the nucleotide sequence of wild type exodomain of human
PAR4.2.4. SDS–PAGE and immunoblotting
PAR exodomains were separated on 16.5 tris–tricine SDS–poly-
acrylamide gels (BioRad, Hercules, CA) and stained with G250
Coomassie Blue (BioRad) or transferred to nitrocellulose for immuno-
blotting. Anti-PAR4 peptide polyclonal antibodies were generated in
goats by injecting peptide SILPAPRGYPGQ into goats (Quality Con-
trol Biochemicals, Hopkinson, MA) [11]. This sequence covers the
thrombin cleavage site on the PAR4 exodomain.
2.5. Binding experiments
Peptide RPPGC or PAR4-wt (1 lg/well) in 0.1 M Na2CO3, pH 9.6,
was bound to microtiter plate wells (F96 CERT.MAXISORP, #
439454, Nunc-Immuno Plate, Fisher Scientific, Chicago, IL) by incu-
bation at 4 C overnight. Following incubation, wells were washed
with 10 mM NaH2PO4, 150 mM NaCl, pH 7.4, containing 0.05%
Tween 20 (PBS-Tween). For experiments in which RPPGC was linked
to plates, the wells were blocked with 1% gelatin and the bound
RPPGC was incubated with 30 lM biotinylated SIL12 (biotin-SIL-
PAPRGYPGQ) in the presence or absence of various peptides for 1
h at 37 C. For experiments in which PAR4-wt was linked to plates,
the wells were blocked with 1% gelatin and the bound PAR4-wt was
incubated with 15 lM RPPGFK-biotin in the presence or absence of
various peptides, PAR1-wt, PAR4-wt or PAR4 mutants for 1 h at
37 C. Following incubation, cells were washed with PBS-Tween and
the bound biotin-SIL12 or RPPGFK-biotin was detected by using Im-
mune-Pure streptavidin horseradish peroxidase conjugate (Pierce
Chemical Co., Rockville, IL) and peroxidase-specific fast reacting sub-
strate, turbo-3, 3 0, 5, 5 0-tetramethylbenzidine (turbo-TMB, Pierce) as
previously described [14]. The color reaction was stopped by the addi-
tion of 1 M phosphoric acid and the reaction was quantitated by mea-
suring the absorbance at 450 nm in a Microplate auto reader EL311
(Bio-Tek, Winooski, VT).2.6. Proteolysis of PAR4 exodomain
PAR4 exodomain (30 lM) in 10 mM NaH2PO4, 150 mM NaCl, pH
7.4, was incubated for 15 min at 37 C with 100–1000 lM rOicPGF
[12]. The reaction was initiated by the addition of c-thrombin (20
nM final concentration) (Haematologic Technologies, Essex Junction,
VT). The reaction was stopped at 60 min and separated on SDS–
PAGE.2.7. Hydrolysis of chromogenic substrate
rOicPGF (50 lM) was incubated with c-thrombin (1 nM) for 5 min
at 25 C. The reaction was initiated by the addition of Sar-Pro-Arg-
paranitroanalide (1 mM) (Sigma) and the absorbance was monitored
at 405 nm for 16 min.3. Results
Previous studies showed that the ACE breakdown product
of bradykinin, RPPGF, prolonged the bleeding time and de-
layed the time to thrombosis in a mouse carotid injury model
[12]. Since mouse platelets do not express PAR1, these peptides
likely inhibited mouse platelet aggregation by blocking mouse
PAR4. Investigations were performed to determine if RPPGF
and related analogs also bound human PAR4.
A peptide that encompassed the thrombin binding and
cleavage site on human PAR4, biotinylated S41ILPAPR-
GYPGQ52 (biotin-SIL12), specifically bound to peptide
RPPGC linked to microtiter plates (Fig. 1). The interaction
of biotin-SIL12 with RPPGC was blocked by increasing con-
centrations of soluble RPPGF, rOicPGF, or unlabeled SIL12
with an IC50 at 1 mM. However, a scrambled peptide of
RPPGF, FPRPG, did not interfere with biotin-SIL12 binding
to RPPGC (Fig. 1).
Next, recombinant exodomain of PAR4 from Gly18-Arg78
was prepared (Fig. 2). On reduced SDS–PAGE, the PAR4
Fig. 3. Inhibition of RPPGFK-biotin binding to PAR4-wt. Recombi-
nant PAR4-wt (1 lg/well) in 0.1 M Na2CO3, pH 9.6, was linked to
microtiter plate wells by overnight incubation at 4 C. After washing
the wells with 0.01 M sodium phosphate and 0.15 M NaCl (pH 7.4)
containing 0.05% Tween and blocking with 1% gelatin, the bound
protein was incubated with 15 lM RPPGFK-biotin in the absence or
presence of increasing concentrations (10–1000 lM) of RPPGF (black
circle), rOciPGF (blue solid triangle) or WPRPG (red square). The
RPPGFK-biotin bound to the cuvette well was detected with strep-
tavidin horseradish peroxidase followed by peroxidase specific sub-
strate and quantitated by reading absorbance at 450 nm. The data are
normalized to wells containing no inhibitor that represents 100%
binding. The data are means ± S.D. of three experiments.
Fig. 1. Inhibition of biotin-SIL12 binding to RPPGC. RPPGC (1 lg/
well) in 0.1 M Na2CO3, pH 9.6, was linked to microtiter plate wells by
overnight incubation at 4 C. After washing the wells with 0.01 M
sodium phosphate and 0.15 M NaCl (pH 7.4) containing 0.05% Tween
and blocking with 1% gelatin, the bound protein was incubated with 30
lM biotin-SIL12 in the absence or presence of increasing concentra-
tions of unlabeled SIL12 (), RPPGF (s), FPRPG (m) or rOicPGF
(n). The biotin-SIL12 bound to the cuvette well was detected with
streptavidin horseradish peroxidase followed by peroxidase specific
substrate and quantitated by reading absorbance at 450 nm. The data
are normalized to wells containing no inhibitor that represents 100%
binding. The data are means ± S.D. of three experiments.
Fig. 2. Expression of wild type and mutant PAR4. Recombinant
PAR4-wt and PAR4 mutants were separated by SDS–PAGE and
stained with Coomassie G250 (on left) or transferred to nitrocellulose
and blotted with anti-PAR4 antibodies (on right). The figure is a
representative experiment.
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than the expected size of 6.44 kDa and there was a minor
bands at 16.9 kDa. To positively identify the major and min-
or bands seen on SDS–PAGE, N-terminal sequencing and
MALDI-TOF mass spectrometry was performed. With the
exception of a N-terminal leucine from the expression system,
the first nine amino acids of these proteins were identical
(LGGTQTPSVY. . .) and were the expected amino acids from
the exodomain of PAR4 starting at position 18, indicating that
the upper band is a dimer of the rPAR4 exodomain [15]. On
mass spectrometry, there were two significant peaks identified
at 6.435 and 12.874 kDa, respectively, corresponding to the ex-
pected size of PAR4-wt and its dimer. Additionally, PAR4-wt
was recognized by an immunoblot with an anti-PAR4 poly-
clonal antibody (Fig. 2), but not by antibodies to PAR1 or
PAR3 (data not shown).
RPPGFK-biotin was found to specifically bind to exodo-
main PAR4-wt linked to microtiter plates. This interaction
was blocked by soluble RPPGF (IC50 = 0.71 mM) or rOicPGF
(IC50 = 0.45 mM), however, at 1 mM the pentapeptide
WPPGF showed 52% less inhibition than the other peptides
(Fig. 3). These data indicate that the N-terminal arginine of
RPPGF participated in its binding to PAR4-wt. These results
were consistent with previous findings that biotin-GRPPGF,
that had its N-terminal arginine blocked, did not bind to pep-
tide SIL12 or PAR1-wt exodomain (data not shown). How-
ever, the N-terminal arginine was not exclusively involved in
binding because at concentrations less than 300 lM there
was no difference in the inhibition of binding by WPPGF or
the other peptides, indicating that additional amino acids
interacted as well.
Since RPPGF binds to PAR4-wt, investigations next mapped
the RPPGF binding site on the exodomain of PAR4. Alanine
site-directed mutagenesis of the exodomain of PAR4 was per-
formed on Pro46 and Pro44 adjacent to the thrombin cleavagesite of PAR4, since RPPGF bound to a peptide that contains
the thrombin cleavage site (S41ILPAPRGYPGQ52) (Table 1
and Fig. 1). The recombinant PAR4 alanine substitution mu-
tants were 6410 Da (PAR4-P44A and PAR4-P46A) and 6380
Da (PAR4-P44A/P46A) as determined by mass spectrometry
(data not shown) and were recognized by polyclonal antibodies
to PAR4 (Fig. 2). However, when both prolines were changed
to alanine, there was reduced antigen recognition by the poly-
clonal antibody reared to peptide SILPAPRGYPGQ, suggest-
ing that the prolines in the peptide were prominent epitopes
(Fig. 2). RPPGFK-biotin binding to recombinant PAR4-wt
linked to microtiter plates was blocked by soluble PAR1-wt,
PAR4-wt, and PAR4-P44A with an IC50 of 243, 215, and 235
lM, respectively (Fig. 4). Alternatively, mutagenesis of Pro46
either alone or in the presence of the Pro44 mutation resulted
in forms of recombinant PAR4 that did not compete
Fig. 5. rOicPGF inhibits proteolysis of the PAR4 exodomain by c-
thrombin. (A) rOicPGF inhibition of c-thrombin cleavage of PAR4
exodomain. Recombinant PAR4-wt (30 lM) in 0.01 M sodium
phosphate and 0.15 M NaCl (pH 7.4) was incubated with rOicPGF
(100–1000 lM) for 15 min at 37 C. The reactions were initiated by the
addition of c-thrombin (20 nM final concentration) and proceeded for
60 min. The reactions were separated by SDS–PAGE and stained with
G250 Coomassie Blue. The lane marked ‘‘PAR4’’ is the undigested
starting material. The figure is a representative experiment. (B) No
rOicPGF inhibition of c-thrombin hydrolysis of a chromogenic
substrate. c-thrombin (1 nM) was incubated with (m) or without (d)
rOicPGF (50 lM) for 5 min at 25 C. The reaction was initiated by the
addition of the chromogenic substrate Sar-Pro-Arg-paranitroanalide
(1 mM) and hydrolysis of the substrate was monitored over 16 min.
These data are means ± standard deviation of three replicates.
Fig. 4. Inhibition of RPPGFK-biotin binding to PAR4. Recombinant
PAR4-wt (1 lg/well) in 0.1 M Na2CO3, pH 9.6, was linked to
microtiter plate wells by overnight incubation at 4 C. After washing
the wells with 0.01 M sodium phosphate and 0.15 M NaCl (pH 7.4)
containing 0.05% Tween and blocking with 1% gelatin, the bound
protein was incubated with 15 lM RPPGFK-biotin in the absence or
presence of increasing concentrations of PAR1-wt (black circle),
PAR4-wt (grey square), PAR4-P44A (red triangle), PAR4-P46A
(green triangle) or PAR4-P44A/P46A (blue diamond). The
RPPGFK-biotin bound to the cuvette well was detected with strep-
tavidin horseradish peroxidase followed by peroxidase specific sub-
strate and quantitated by reading absorbance at 450 nm. The data are
normalized to wells containing no inhibitor that represents 100%
binding. The data are means ± S.D. of three experiments.
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These data indicated that Pro46 was critical for the interaction
of the arginine of RPPGF with the exodomain of PAR4.
Investigations next determined if binding of an analog of
RPPGF to the PAR4 exodomain inhibited its proteolysis of
PAR4 by thrombin. The exodomain of PAR4 was fully
cleaved by 20 nM c-thrombin in 60 min (Fig. 5A). The prote-
olysis was progressively inhibited by 100–750 lM rOicPGF
(molar ratio of rOicPGF:c-thrombin is 37 500:1) (Fig. 5A).
This effect was completely due to rOicPGF binding to the
exodomain of PAR4 because 50 lM rOicPGF did not inhibit
1 nM c-thrombin hydrolysis of Sar-Pro-Arg-paranitroanalide
(molar ratio of rOicPGF:c-thrombin is 50 000:1) (Fig. 5B).
These data indicated that rOicPGF inhibited PAR4 proteolysis
by c-thrombin at concentrations that do not affect the enzy-
matic activity of c-thrombin.4. Discussion
In this report, we demonstrate that the ACE breakdown
product of bradykinin, RPPGF, or an analog, rOicPGF, binds
to the exodomain of human PAR4 at Pro46, the P2 position, to
prevent its proteolysis by thrombin. Further, our studies indi-
cate that the amino terminal arginine of these peptides is essen-
tial for this interaction. The interaction of RPPGF with
human PAR4 exodomain is consistent with previous studies
in which RPPGF and analogs delay the time to thrombosis
in mice and inhibit thrombin-induced platelet aggregation in
mouse platelets [12].
Bradykinin inhibits thrombin-induced human platelet aggre-
gation [16]. The inhibitory properties of bradykinin map to the
peptide RPPGF, a naturally occurring biological peptide thatis the terminal ACE breakdown product of bradykinin [16].
Bradykinin, RPPGF and analogs inhibit platelet activation
by two mechanisms: they bind to the active site of thrombin
and to the exodomain of PAR1 at the thrombin cleavage site
[11,16,17]. The present report expands the thrombin inhibitory
mechanism of RPPGF and related compounds by showing
that they also bind to the exodomain of PAR4. Thus, a natu-
rally occurring peptide binds to thrombin and to PAR1 and
PAR4. Recent additional data also indicate that the RPPGF
(unpublished) and rOicPGF also inhibit the active site of coag-
ulation factor VIIa if incubated in the absence of tissue factor
[12].
The binding site of RPPGF and analogs has been mapped to
be near the thrombin cleavage site for both PAR1 and PAR4.
There is relatively little sequence identity between PAR1 and
PAR4 in this region, so it is unexpected that these peptides
bind to both receptors [11,15,18]. These data suggest that there
must be similarities in the three-dimensional structure of the
PARs in this region that allow these peptides to bind. Using
NMR, Cleary et al. [19] have demonstrated that Leu43 at P5
of PAR4 (L43PAPR) is flexible and can exist in two conforma-
tions in the presence of thrombin; the side chain of Leu43 inter-
acts with Pro44 or Pro46. A three-dimensional structure of
Leu43 interacting with Pro46 is similar to the structure of a
PAR1 peptide that was co-crystallized with a-thrombin [20].
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the same conformation as the P4–P1 position of PAR1
(L38DPR) [20]. These data suggest that PAR1 and PAR4 can
exist in similar three-dimensional structures, which make it
plausible that a single agent can interact with both receptors.
In the alanine mutants PAR4-P46A and PAR4-P44A/P46A,
it is unlikely that Leu43 is able to interact with the alanine at
the P2 position and, consequently, the conformation around
the P5–P2 position is disrupted resulting in the loss of RPPGF
binding. Recognition of the conformational similarity between
thrombin substrates is not unique. A monoclonal antibody
that inhibits fibrinogens Aa-chain cross-linking also directly
inhibits factor XIIIa [21]. Similarly, just as there is conforma-
tional conservation among thrombin substrates, the S1 pockets
of serine proteases are also conserved as indicated by the lack
of complete substrate specificity of serine proteases on chro-
mogenic substrates. Further, recent evidence suggests that
the S1 pockets of thrombin and factor VIIa have similar struc-
tures [22]. This information may explain how RPPGF and
analogs can interact with PAR1 and PAR4 exodomains as well
as the active sites of thrombin and factor VIIa [11,12].
PAR antagonists that have been developed to date prevent
the activation of the receptor by interfering with the ligand
binding site or specifically interfering with signaling through
the intracellular loops [8–10]. In each case, the antagonist acts
after the receptor has been proteolyzed by thrombin and thus
interferes with the signaling mechanism of the activated recep-
tor. Since the ligand for each of the PARs and the downstream
signaling pathways is unique, these kinds of strategies for
interfering with the PARs require agents unique for each
receptor. In contrast, the mechanism of RPPGF and its ana-
logs inhibition of PAR activation is quite different. These lat-
ter compounds interfere with the proteolysis of both PAR
exodomains and, as a result, the activation of both receptors,
allowing for a single agent that blocks thrombin-induced plate-
let activation of both PAR1 and 4.
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